The Honest Answer — With a Catch

Hearing aids are expensive, and the search for something that actually works without draining savings is completely reasonable. Nearly 28.8 million U.S. adults could benefit from hearing aids, yet only 16% of those aged 20–69 who need them actually use them. Cost is one of the biggest reasons people delay — often for close to a decade.

So here's the straight answer: yes, one sub-$100 device earned a "B" SoundGrade from HearAdvisor, a respected independent testing lab. That's the best result in its price tier. But most others scored far worse, and some actually made hearing worse than wearing nothing at all.

The FDA's 2022 OTC ruling opened the door to more affordable options — and that's genuinely good news. But rock-bottom price points come with real performance trade-offs that lab data makes impossible to ignore. This article works through that data so the decision is based on facts, not marketing claims from any brand.

What Independent Testing Actually Found

HearAdvisor, an independent lab, tests OTC hearing aids against standardized speech-clarity benchmarks. Their data on sub-$100 devices tells a clear story.

* Oricle does not currently have published HearAdvisor lab scores. We note this openly — independent testing is something we're working toward.

The JLab Hear OTC stands out as the lone exception at this price point, earning a "B" SoundGrade — genuinely impressive for the tier. But "best in class" among sub-$100 devices still means significant limitations in the real-world situations where hearing aids matter most: restaurants, family gatherings, phone calls.

Audiologists reviewing this category have not been diplomatic. Reviewers at The Senior List described anything under $100 as "a glorified earbud that will not actually help with hearing loss." HearAdvisor's own summary of this tier confirmed that "most devices in this price range are awful." That's not Oricle's assessment — that's the independent lab's conclusion.

One more distinction most buyers miss

Many sub-$100 products marketed as hearing aids are actually PSAPs — Personal Sound Amplification Products. PSAPs are not regulated as medical devices. They are not designed to address hearing loss, and they don't have to meet the same safety or performance standards as OTC hearing aids. Checking FDA registration before purchasing anything in this price range is worth the two minutes it takes.

Why Sub-$100 Devices Struggle

Building a quality hearing aid requires specific hardware and software, and certain features simply cannot be included at this price point. Audiogram-based programming, AI-powered noise reduction, multi-environment settings, and telehealth audiologist support all require investment that sub-$100 devices skip entirely.

The biggest real-world consequence is performance in noise. Restaurants, family dinners, group conversations — these are the exact situations where people need hearing support most. A device that works reasonably well in a quiet room but falls apart when background noise enters isn't solving the actual problem.

FDA regulations also cap OTC hearing aids at 20 dB of average gain and a maximum output of 117 dB SPL. These limits mean OTC devices — regardless of price — are only appropriate for mild to moderate perceived hearing loss. If hearing loss is more significant, no sub-$100 device will come close to meeting the need.

And the satisfaction data makes the pattern plain: budget OTC hearing aids under $400 have a user satisfaction rate of just 48% according to MarkeTrak 2025. Compare that to 76–83% for higher-tier OTC and traditional devices. Nearly half of budget buyers end up unhappy. That's not a small group of edge cases — that's the typical outcome.

The Hidden Cost of Getting This Wrong

This goes beyond sound quality or wasted money. Untreated hearing loss — including hearing loss that's nominally "addressed" by a device that scores 0 out of 5 — carries measurable long-term health consequences.

A device that doesn't actually improve hearing creates the impression that the issue has been handled, while the brain continues to miss critical auditory input. That gap matters.

Alzheimer's Research UK reports that hearing aid users are roughly 50% less likely to develop mild cognitive impairment, and that hearing aid use may reduce the risk of long-term cognitive decline by 19%. These figures come from population research on people using devices that actually function — not devices that perform below baseline.

This is why the question of device quality matters beyond sound comfort. Choosing a device that doesn't perform is not a neutral outcome — it's a missed opportunity for something more consequential.

Where Real OTC Value Actually Starts

Rather than asking "what's the cheapest hearing aid available," the more useful question is: where does real value begin?

The data points to a clear answer: the OTC value sweet spot starts around $150–$400 per pair. At this range, devices include technology that can genuinely improve hearing — rechargeable batteries, meaningful noise reduction, audiologist-reviewed programming, and post-sale support.

For context on value: MarkeTrak 2025 found that OTC hearing aids average $502 per pair, compared to $3,000–$7,000 for traditional prescription devices. Hearing aid costs overall have dropped 42% since 2018, making quality devices more accessible than at any point in the category's history. Mid-tier OTC is still dramatically more affordable than the traditional route — and it's where performance begins to match the promise.

Oricle's lineup — from $149.99 to $289.99 per pair — sits directly in this sweet spot. Every device is FDA-registered, designed with audiologists, rechargeable, and backed by a 30-day satisfaction guarantee and lifetime customer support. Over 100,000 customers have made the switch.

What to Look For Before Buying Any Budget Hearing Aid

No matter the budget, these six criteria are worth checking before purchasing from any brand.